Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - risperidone, quantity: 3 mg - tablet - excipient ingredients: magnesium stearate; lactose monohydrate; colloidal anhydrous silica; pregelatinised maize starch; sodium lauryl sulfate; microcrystalline cellulose; titanium dioxide; hypromellose; purified talc; quinoline yellow aluminium lake; macrogol 4000; macrogol 400 - ozidal is indicated for - treatment of schizophrenia and related psychoses; short-term treatment of acute mania associated with bipolar 1 disorder; treatment (up to 12 weeks) of psychotic symptoms or persistent agitations or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type; treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (eg. aggression, impulsivity and self-injurious behaviours) are prominent; treatment of behavioural disorders associated with autism in children and adolescents.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - risperidone, quantity: 2 mg - tablet - excipient ingredients: sodium lauryl sulfate; lactose monohydrate; colloidal anhydrous silica; microcrystalline cellulose; pregelatinised maize starch; magnesium stearate; titanium dioxide; hypromellose; sunset yellow fcf aluminium lake; purified talc; macrogol 4000; macrogol 400 - ozidal is indicated for - treatment of schizophrenia and related psychoses; short-term treatment of acute mania associated with bipolar 1 disorder; treatment (up to 12 weeks) of psychotic symptoms or persistent agitations or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type; treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (eg. aggression, impulsivity and self-injurious behaviours) are prominent; treatment of behavioural disorders associated with autism in children and adolescents.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - risperidone, quantity: 1 mg - tablet - excipient ingredients: microcrystalline cellulose; pregelatinised maize starch; colloidal anhydrous silica; lactose monohydrate; magnesium stearate; sodium lauryl sulfate; titanium dioxide; propylene glycol; hypromellose; hyprolose; purified talc - ozidal is indicated for - treatment of schizophrenia and related psychoses; short-term treatment of acute mania associated with bipolar 1 disorder; treatment (up to 12 weeks) of psychotic symptoms or persistent agitations or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type; treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (eg. aggression, impulsivity and self-injurious behaviours) are prominent; treatment of behavioural disorders associated with autism in children and adolescents.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - risperidone, quantity: 0.5 mg - tablet - excipient ingredients: pregelatinised maize starch; magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose; sodium lauryl sulfate; lactose monohydrate; titanium dioxide; hypromellose; purified talc; macrogol 4000; iron oxide red; macrogol 400 - ozidal is indicated for - treatment of schizophrenia and related psychoses; short-term treatment of acute mania associated with bipolar 1 disorder; treatment (up to 12 weeks) of psychotic symptoms or persistent agitations or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type; treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (eg. aggression, impulsivity and self-injurious behaviours) are prominent; treatment of behavioural disorders associated with autism in children and adolescents.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - risperidone -

Australia - English - Department of Health (Therapeutic Goods Administration)

ranbaxy australia pty ltd - risperidone -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

ranbaxy (malaysia) sdn. bhd. - risperidone -

United States - English - NLM (National Library of Medicine)

primary pharmaceuticals, inc - drug facts, camphor 2%................topical analgesic, lidocaine 2.5%............ topical analgesic, methyl salicylate 4%....topical analgesic, (nsaid: nonsteroidal anti-inflammatory drug) - diclofenac sodium topical solution is a nonsteroidal anti-inflammatory drug (nsaid) indicated for the treatment of signs and symptoms of osteoarthritis of the knee(s). diclofenac sodium topical solution is contraindicated in patients with a known hypersensitivity to diclofenac sodium or any other component of diclofenac sodium topical solution. diclofenac sodium topical solution is contraindicated in patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients [see warnings and precautions (5.7, 5.10)]. diclofenac sodium topical solution is contraindicated in the setting of coronary artery bypass graft (cabg) surgery [see warnings and precaution

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

jurox pty limited - carprofen - oral tablet - carprofen anti-inflammatory-nonsteroidal active 20.0 mg/tb - musculoskeletal system - dog | bitch | castrate | puppy - anti-inflammatory agent | antipyretic | bone soreness | bruising | bursitis | inflammatory rheumatic arthrit | joint disease | ligament sprains | muscle soreness | osteoarthritis | platelet activity | rheumatism | sprains | strains | tendon sprains | traumatic swelling

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

jurox pty limited - carprofen - oral tablet - carprofen anti-inflammatory-nonsteroidal active 50.0 mg/tb - musculoskeletal system - dog | bitch | castrate | puppy - anti-inflammatory agent | antipyretic | bone soreness | bruising | bursitis | inflammatory rheumatic arthrit | joint disease | ligament sprains | muscle soreness | osteoarthritis | platelet activity | rheumatism | sprains | strains | tendon sprains | traumatic swelling